180 related articles for article (PubMed ID: 25179840)
41. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
Narui K; Ishikawa T; Shimizu D; Yamada A; Tanabe M; Sasaki T; Oba MS; Morita S; Nawata S; Kida K; Mogaki M; Doi T; Tsugawa K; Ogata H; Ota T; Kosaka Y; Sengoku N; Kuranami M; Niikura N; Saito Y; Suzuki Y; Suto A; Arioka H; Chishima T; Ichikawa Y; Endo I; Tokuda Y
Breast; 2019 Oct; 47():1-9. PubMed ID: 31229857
[TBL] [Abstract][Full Text] [Related]
42. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
43. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
44. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer.
Zhu X; Chen L; Huang B; Wang Y; Ji L; Wu J; Di G; Liu G; Yu K; Shao Z; Wang Z
Sci Rep; 2020 Jan; 10(1):225. PubMed ID: 31937819
[TBL] [Abstract][Full Text] [Related]
45. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
Malamou-Mitsi V; Gogas H; Dafni U; Bourli A; Fillipidis T; Sotiropoulou M; Vlachodimitropoulos D; Papadopoulos S; Tzaida O; Kafiri G; Kyriakou V; Markaki S; Papaspyrou I; Karagianni E; Pavlakis K; Toliou T; Scopa C; Papakostas P; Bafaloukos D; Christodoulou C; Fountzilas G
Ann Oncol; 2006 Oct; 17(10):1504-11. PubMed ID: 16968874
[TBL] [Abstract][Full Text] [Related]
47. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
48. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
[TBL] [Abstract][Full Text] [Related]
49. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Gasparini P; Cascione L; Fassan M; Lovat F; Guler G; Balci S; Irkkan C; Morrison C; Croce CM; Shapiro CL; Huebner K
Oncotarget; 2014 Mar; 5(5):1174-84. PubMed ID: 24632568
[TBL] [Abstract][Full Text] [Related]
50. EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma.
Shen WW; Bièche I; Fuhrmann L; Vacher S; Vincent-Salomon A; Torrino S; Lamaze C
Sci Rep; 2020 May; 10(1):7998. PubMed ID: 32409676
[TBL] [Abstract][Full Text] [Related]
51. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy.
Treré D; Brighenti E; Donati G; Ceccarelli C; Santini D; Taffurelli M; Montanaro L; Derenzini M
Ann Oncol; 2009 Nov; 20(11):1818-23. PubMed ID: 19556322
[TBL] [Abstract][Full Text] [Related]
52. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
M-Rabet M; Cabaud O; Josselin E; Finetti P; Castellano R; Farina A; Agavnian-Couquiaud E; Saviane G; Collette Y; Viens P; Gonçalves A; Ginestier C; Charafe-Jauffret E; Birnbaum D; Olive D; Bertucci F; Lopez M
Ann Oncol; 2017 Apr; 28(4):769-776. PubMed ID: 27998973
[TBL] [Abstract][Full Text] [Related]
53. Triple negative breast cancer - BCL2 in prognosis and prediction. Review.
Bouchalova K; Kharaishvili G; Bouchal J; Vrbkova J; Megova M; Hlobilkova A
Curr Drug Targets; 2014; 15(12):1166-75. PubMed ID: 25374001
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Adams S; Gray RJ; Demaria S; Goldstein L; Perez EA; Shulman LN; Martino S; Wang M; Jones VE; Saphner TJ; Wolff AC; Wood WC; Davidson NE; Sledge GW; Sparano JA; Badve SS
J Clin Oncol; 2014 Sep; 32(27):2959-66. PubMed ID: 25071121
[TBL] [Abstract][Full Text] [Related]
55. BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
Ishikawa T; Narui K; Tanabe M; Kida K; Oba MS; Yamada A; Ichikawa Y; Endo I
Eur J Surg Oncol; 2016 Jul; 42(7):999-1001. PubMed ID: 27041672
[TBL] [Abstract][Full Text] [Related]
56. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy.
Lai SF; Chen YH; Kuo WH; Lien HC; Wang MY; Lu YS; Lo C; Kuo SH; Cheng AL; Huang CS
Ann Surg Oncol; 2016 Nov; 23(12):3860-3869. PubMed ID: 27436202
[TBL] [Abstract][Full Text] [Related]
57. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
[TBL] [Abstract][Full Text] [Related]
58. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
59. Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
Kim MC; Choi JE; Lee SJ; Bae YK
Ann Surg Oncol; 2016 Oct; 23(11):3524-3530. PubMed ID: 27278204
[TBL] [Abstract][Full Text] [Related]
60. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
Ozretic P; Alvir I; Sarcevic B; Vujaskovic Z; Rendic-Miocevic Z; Roguljic A; Beketic-Oreskovic L
Int J Biol Markers; 2018 Jan; 33(1):109-115. PubMed ID: 28777433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
